DK0983273T3 - Ethylenglycolestere af monohydrobenzoporphyrinderivater som fotoaktive midler - Google Patents

Ethylenglycolestere af monohydrobenzoporphyrinderivater som fotoaktive midler

Info

Publication number
DK0983273T3
DK0983273T3 DK98921294T DK98921294T DK0983273T3 DK 0983273 T3 DK0983273 T3 DK 0983273T3 DK 98921294 T DK98921294 T DK 98921294T DK 98921294 T DK98921294 T DK 98921294T DK 0983273 T3 DK0983273 T3 DK 0983273T3
Authority
DK
Denmark
Prior art keywords
ethylene glycol
glycol esters
photoactive agents
monohydrobenzoporphyrin
derivatives
Prior art date
Application number
DK98921294T
Other languages
Danish (da)
English (en)
Inventor
Ethan Sternberg
Anna M Richter
David W C Hunt
Jain Ashok
David Dolphin
Julia G Levy
Ashok Jain
Elizabeth M Waterfield
Original Assignee
Univ British Columbia
Quadra Logic Tech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ British Columbia, Quadra Logic Tech Inc filed Critical Univ British Columbia
Application granted granted Critical
Publication of DK0983273T3 publication Critical patent/DK0983273T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DK98921294T 1997-05-07 1998-05-06 Ethylenglycolestere af monohydrobenzoporphyrinderivater som fotoaktive midler DK0983273T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US85249497A 1997-05-07 1997-05-07
PCT/CA1998/000468 WO1998050387A1 (fr) 1997-05-07 1998-05-06 Esters d'ethyleneglycol de derives de monohydrobenzopophyrine utilises comme agents photosensibles

Publications (1)

Publication Number Publication Date
DK0983273T3 true DK0983273T3 (da) 2002-04-22

Family

ID=25313492

Family Applications (1)

Application Number Title Priority Date Filing Date
DK98921294T DK0983273T3 (da) 1997-05-07 1998-05-06 Ethylenglycolestere af monohydrobenzoporphyrinderivater som fotoaktive midler

Country Status (21)

Country Link
US (2) US5929105A (fr)
EP (2) EP1177795B1 (fr)
JP (1) JP3378889B2 (fr)
KR (1) KR100397131B1 (fr)
CN (1) CN1113882C (fr)
AR (1) AR012673A1 (fr)
AT (1) ATE211473T1 (fr)
AU (1) AU741070B2 (fr)
CA (1) CA2284879C (fr)
CZ (1) CZ294715B6 (fr)
DE (1) DE69803376T2 (fr)
DK (1) DK0983273T3 (fr)
ES (2) ES2437790T3 (fr)
HK (1) HK1042439B (fr)
HU (1) HU221754B1 (fr)
IL (1) IL132066A (fr)
NO (1) NO314264B1 (fr)
NZ (1) NZ338031A (fr)
PL (1) PL202341B1 (fr)
PT (1) PT983273E (fr)
WO (1) WO1998050387A1 (fr)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6756396B1 (en) * 1997-05-07 2004-06-29 Qlt Inc. Ethylene glycol esters as photoactive agents
US6364907B1 (en) 1998-10-09 2002-04-02 Qlt Inc. Method to prevent xenograft transplant rejection
US6331235B1 (en) * 1998-12-11 2001-12-18 The University Of British Columbia Chiral separation of benzoporphyrin derivative mono-and di-acids by laser-induced fluorescence capillary electrophoresis
US6344050B1 (en) 1998-12-21 2002-02-05 Light Sciences Corporation Use of pegylated photosensitizer conjugated with an antibody for treating abnormal tissue
US6602274B1 (en) * 1999-01-15 2003-08-05 Light Sciences Corporation Targeted transcutaneous cancer therapy
US6454789B1 (en) 1999-01-15 2002-09-24 Light Science Corporation Patient portable device for photodynamic therapy
WO2000041726A2 (fr) 1999-01-15 2000-07-20 Light Sciences Corporation Therapie vasculaire non invasive
WO2000051638A1 (fr) * 1999-02-26 2000-09-08 Qlt Phototherapeutics Inc. Therapie photodynamique associee a des facteurs induisant l'apoptose
GB9905911D0 (en) 1999-03-15 1999-05-05 Photocure As Method
US6609014B1 (en) 1999-04-14 2003-08-19 Qlt Inc. Use of PDT to inhibit intimal hyperplasia
US20020022032A1 (en) * 1999-04-23 2002-02-21 Curry Patrick Mark Immuno-adjuvant PDT treatment of metastatic tumors
US7122568B1 (en) 1999-11-17 2006-10-17 Qlt, Inc. Use of low-dose PDT to inhibit restenosis
US20040208855A1 (en) * 1999-11-17 2004-10-21 Allison Beth Anne Use of PDT to inhibit intimal hyperplasia
US20020049247A1 (en) * 2000-01-12 2002-04-25 Chen James C. Novel treatment for eye disease
WO2001085212A2 (fr) * 2000-05-08 2001-11-15 The University Of British Columbia Systemes d'apport de medicament, destines a une therapie photodynamique
AU2001258117A1 (en) 2000-05-08 2001-11-20 The University Of British Columbia Supports for photosensitizer formulations
EP1339862B1 (fr) * 2000-11-29 2014-01-08 PCI Biotech AS Internalisation photochimique pour introduction de molecules dans le cytosol par des vecteurs viraux
PT1346059E (pt) * 2000-11-29 2012-06-01 Pci Biotech As Internalização fotoquímica para distribuição de moléculas no citosol
US6984395B2 (en) * 2001-04-11 2006-01-10 Qlt, Inc. Drug delivery system for hydrophobic drugs
AU2002344234B2 (en) * 2001-05-31 2007-11-08 Miravant Pharmaceuticals, Inc. Metallotetrapyrrolic photosensitizing agents for use in photodynamic therapy
DE60230636D1 (de) * 2001-08-22 2009-02-12 Univ Montana State Porphyrine mit verbesserten multi-photonen-absorptionsquerschnitten für die photodynamische therapie
EP1465590B1 (fr) * 2001-11-02 2008-03-26 The Governors Of The University Of Alberta Formulations contenant un lipide-polyethylene glycol
CA2466425A1 (fr) 2001-11-09 2003-05-15 Qlt Inc. Therapie photodynamique destinee a traiter la chute des cheveux
US7264629B2 (en) 2001-11-09 2007-09-04 Qlt, Inc. Photodynamic therapy for the treatment of hair loss
CA2437638A1 (fr) * 2003-08-20 2005-02-20 John Robert North Therapie photodynamique
CA2457214A1 (fr) * 2004-02-06 2005-08-06 Qlt Inc. Therapie photodynamique pour le traitement de l'acne
US20110070154A1 (en) * 2008-08-13 2011-03-24 Hyde Roderick A Artificial cells
AU2010270797B2 (en) 2009-07-08 2015-03-19 Dermira (Canada), Inc. TOFA analogs useful in treating dermatological disorders or conditions
CN102844044B (zh) 2010-02-04 2016-10-26 摩尔弗泰克有限公司 氯毒素多肽和结合物及其应用
BR112013017953A2 (pt) 2011-01-13 2017-08-29 Quadra Logic Tech Inc Composição farmacêutica, formulação tópica, método, e, composição fotossensibilizadora
WO2013003507A1 (fr) 2011-06-27 2013-01-03 Morphotek, Inc. Agents multifonction
WO2013063312A1 (fr) 2011-10-25 2013-05-02 Memorial Sloan-Kettering Cancer Center Anticorps anti-psa libres en tant que produits de diagnostic, de pronostic et thérapeutiques pour le cancer de la prostate
CN104703624A (zh) 2012-07-11 2015-06-10 德米拉股份有限公司 局部递送光敏剂的药物组合物及其应用
US9365542B2 (en) 2012-10-26 2016-06-14 Memorial Sloan-Kettering Cancer Center Modulators of resistant androgen receptor
US10113169B2 (en) 2013-12-23 2018-10-30 Memorial Sloan-Kettering Cancer Center Methods and compositions for treating cancer using peptide nucleic acid-based agents

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5095030A (en) * 1987-01-20 1992-03-10 University Of British Columbia Wavelength-specific cytotoxic agents
US5283255A (en) * 1987-01-20 1994-02-01 The University Of British Columbia Wavelength-specific cytotoxic agents
US4920143A (en) * 1987-04-23 1990-04-24 University Of British Columbia Hydro-monobenzoporphyrin wavelength-specific cytotoxic agents
US4883790A (en) 1987-01-20 1989-11-28 University Of British Columbia Wavelength-specific cytotoxic agents
US5171749A (en) 1987-01-20 1992-12-15 University Of British Columbia Wavelength-specific cytotoxic agents
CA2056431A1 (fr) * 1989-06-07 1990-12-08 David Dolphin Photosensibilisation de derives de la porphyrine obtenus par additions diels-alder
US5498710A (en) * 1994-04-22 1996-03-12 Health Research, Inc. Alkyl ether analogues of benzoporphyrin derivatives
CA2288045C (fr) * 1997-05-07 2007-01-23 The University Of British Columbia Nouvelle classe de composes photo-actifs derives de la benzoporphyrine

Also Published As

Publication number Publication date
EP0983273B1 (fr) 2002-01-02
ES2171022T3 (es) 2002-08-16
PT983273E (pt) 2002-06-28
CA2284879A1 (fr) 1998-11-12
NO314264B1 (no) 2003-02-24
PL202341B1 (pl) 2009-06-30
EP1177795B1 (fr) 2013-09-11
US5929105A (en) 1999-07-27
NO995436L (no) 2000-01-04
NZ338031A (en) 2001-04-27
JP2001507369A (ja) 2001-06-05
CA2284879C (fr) 2005-10-25
ES2437790T3 (es) 2014-01-14
EP0983273A1 (fr) 2000-03-08
AU7420798A (en) 1998-11-27
CZ392399A3 (cs) 2000-02-16
DE69803376T2 (de) 2002-08-14
AU741070B2 (en) 2001-11-22
DE69803376D1 (de) 2002-02-28
CZ294715B6 (cs) 2005-02-16
EP0983273B8 (fr) 2002-10-09
US6153639A (en) 2000-11-28
HK1042439B (en) 2014-02-28
KR20010012331A (ko) 2001-02-15
HU221754B1 (hu) 2002-12-28
HUP0003604A2 (hu) 2001-02-28
IL132066A0 (en) 2001-03-19
HUP0003604A3 (en) 2002-04-29
NO995436D0 (no) 1999-11-05
CN1113882C (zh) 2003-07-09
KR100397131B1 (ko) 2003-09-13
CN1254339A (zh) 2000-05-24
IL132066A (en) 2008-06-05
ATE211473T1 (de) 2002-01-15
JP3378889B2 (ja) 2003-02-17
WO1998050387A1 (fr) 1998-11-12
EP1177795A2 (fr) 2002-02-06
AR012673A1 (es) 2000-11-08
EP1177795A3 (fr) 2002-05-29
PL336790A1 (en) 2000-07-17

Similar Documents

Publication Publication Date Title
DK0983273T3 (da) Ethylenglycolestere af monohydrobenzoporphyrinderivater som fotoaktive midler
NO20014412L (no) Forbindelser nyttige som anti-inflammatoriske midler
NO20002173L (no) Pleuromutilin-derivater som antimikrobielle midler
NO20013559L (no) Aromatiske heterocykliske forbindelser som anti- inflammatoriske midler
NO20013671L (no) Substituerte bisycliske derivater nyttige som anticancer midler
NO20002217D0 (no) Cyclopentan-heptansyre, 2-heteroarylalkenylderivater som terapeutiske midler
NO992821D0 (no) Ketobenzamider som calpain-inhibitorer
NO992725D0 (no) 6-Fenylpyridyl-2-amin-derivater anvendelige som NOS-inhibitorer
NO971137D0 (no) Dimetyl-(3-aryl-but-3-enyl)-aminforbindelse som farmasöytiske forbindelser
FI951001A0 (fi) Sulfatoituja alfa-glykolipidijohdannaisia soluadheesioinhibiittoreina
NO960371D0 (no) Piperazinderivater som ter
ATE365276T1 (de) Mehrachsige turbine
NO990435D0 (no) Fremstilling av estere som overflateaktive midler
DE60032726D1 (de) OPTISCHES ZEITBEREICHSREFLEkTOMETER
DK1216250T3 (da) Thienoisoxazolyl- og thienylpyrazolyl-phenoxy- substituerede propylderivater som D4-antagonister
DK0964863T3 (da) Oxazolidinoner som 5-HT2A-antagonister
NO20020457D0 (no) Benzenaminderivater som antikoagulanter
NO20001200D0 (no) Pyrrolopyrrolonderivater som inhibitorer av neurofil elastase
NO993812L (no) (4-piperidinyl)-1H-2benzopyranderivater som er anvendbare som antipsykotiske midler
NO996244D0 (no) Pyrrolidinkarboksylsyrederivater som endotelinantagonister
NO20002321D0 (no) Bifenylderivater som farmasøytiske midler
EE200000239A (et) Uued metüleenbisfosfoonhappe derivaadid
FI980557A0 (fi) Foerfarande vid kalandrering av pappersbana och kalander som tillaempar foerfarandet
NO20021249D0 (no) Tienoisoksazolfenoksyusubstituerte etyl- og propylderivater som D4antagonister
FI973491A0 (fi) Markeringsmaolning och distributionsfoerpackning som anvaender en laogtrycksbehaollare foer densamma